... thedifficulty of obtaining the interest and participatin of individual companies. Segregation of products accordingto market niches and proprietary arguments is limitingthe utilization of promising ... treatment of breast, ovarian, and head and neck cancer. However, in the last decade, the approachesto cancer therapy have change d. In 1998, the approval of trastuzumab for the treatment of breast ... different but potentially synergisticAscierto and Marincola Journal of Translational Medicine 2011, 9:115http://www.translational-medicine.com/content/9/1/115Page 2 of 3mechanisms of action....